HKG:6160

Nomura Adjusts BeOne Medicines' Price Target to HK$288.70 From HK$270.74, Keeps at Buy

BeOne Medicines Posts 627% Jump in H1 Profit; Shares Fall 5%

BeOne Medicines (SHA:688235, HKG:6160) posted first-half attributable net profit of 3.27 billion yuan, up 627% from 449.8 million yuan the previous year.Basic earnings per share jumped to 2.26 yuan from 0.32 yuan, according to a Thursday filing with the Shanghai bourse.Operating revenue climbed 27% year over year to 22.2 billion yuan from 17.5 billion yuan.Shares of the oncology company fell 5% in recent trade on the Shanghai bourse.

BeOne Medicines' Adjusted Q2 Net Income Surges 76%

BeOne Medicines (SHA:688235, HKG:6160) recorded an adjusted net income of $444.5 million in the second quarter of 2026, up 76% from $252.8 million a year prior.Adjusted earnings per American Depository Share rose to $3.84 from $2.25 previously, according to a Wednesday Hong Kong bourse filing.Revenue stood at $1.71 billion in the three months, up 30% from $1.32 billion in the year-ago period.The company attributed the higher profit to a rise in revenue and improved operating leverage.The company raised the 2026 revenue guidance to between $6.6 billion and $6.8 billion.

BeOne Reports Positive Interim Results of Mantle Cell Lymphoma Drug Trial; Shares Down 3%

BeOne Medicines (SHA:688235, HKG:6160) said interim results were positive for the Phase Three MANGROVE trial evaluating Brukinsa (zanubrutinib) plus rituximab as first-line treatment for mantle cell lymphoma.The chemotherapy-free regimen reduced disease progression or death risk by 43% versus bendamustine-rituximab, meeting its primary endpoint, according to a Wednesday filing with the Shanghai bourse.BeOne Medicines plans to present full results at a medical congress and pursue global regulatory submissions in late 2026.Shares of the oncology company were down 3% on the Shanghai bourse.

BeOne Medicines Unit to Pay Additional Income Tax

A Chinese unit of BeOne Medicines (SHA:688235, HKG:6160) will pay income tax of 446 million yuan, including late payment surcharges, after receiving a notice from a local tax authority.The company agreed to modify previously filed tax returns as part of the move, according to a Friday Hong Kong bourse filing.No administrative penalty is involved in this tax matter.

Market Chatter: China Approves 15 Domestic Innovative Drugs

Domestic biopharmaceutical developers captured nearly 80% of China's recent innovative drug clearances, marking a major milestone as local pipelines outpace imports.Fifteen of the 19 innovative drugs cleared by the National Medical Products Administration as of May 21 came from domestic companies, The South China Morning Post reported Wednesday.The regulator has overhauled its approval process specifically to fast-track home-grown innovative drugs to market, according to the report.Among those approved was BeOne Medicines' (SHA:688235, HKG:6160) sonrotoclax, used for treating adult blood cancers, the SCMP wrote.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

US Grants Accelerated Approval to BeOne Medicines' Blood Cancer Treatment Beqalzi

BeOne Medicines (SHA:688235, HKG:6160) said the U.S. Food and Drug Administration granted accelerated approval to Beqalzi to treat a type of rare blood cancer, according to a Thursday filing with the Hong Kong bourse.The drug, also known as sonrotoclax, will be available for adult patients with relapsed or refractory mantle cell lymphoma who have failed at least two lines of system therapy.Continued approval for this indication will remain contingent upon confirmation of clinical benefit in the ongoing trial of the medicine.Beqalzi holds the breakthrough therapy, fast-track, and orphan drug designations in this indication, BeOne said.Shares of the company were up over 2% in pre-market trade.

BeOne Medicines' Net Income Soars in Q1; Revenue Up

BeOne Medicines (SHA:688235, HKG:6160) recorded a first-quarter net income surge as revenue grew year over year.GAAP net income was $227.4 million in the first quarter, up from $1.3 million a year prior. GAAP earnings per American depository share increased to $1.96 from $0.01, according to a Wednesday Hong Kong bourse filing.The oncology company's total revenue jumped to $1.51 billion from $1.12 billion over the period.